the Efficacy and Safety of Vitamin C for Iron Supplementation in Adult IDA Patients

February 21, 2019 updated by: xiao-qin wang, Huashan Hospital

The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA)

IDA patients ofen receive ferrous succinate treatment to speed up the recovery of anemia, the doctor will prescribe ferrous succinate with or without vitamin C according to their own preferences. In theory, only the divalent iron can be absorbed in duodenum and upper jejunum, vitamin C can oxidize ferric iron into divalent iron and maintains a certain degree of acidity in the intestine, and then promotes the absorption of iron. In current clinical practice, it's lack of randomized controlled trial(RCT) about the efficacy and safety of vitamin C for iron supplementation in patients with IDA. In this study, the efficacy and safety of vitamin C for iron supplementation in adult IDA patients are explored by RCT. The dosage regimens of ferrous succinate with or without vitamin C are randomly assigned to patients who meet the inclusion criteria, and these patients are followed up every two weeks. On the one hand, whether the addition of vitamin C can accelerate the recovery of anemia is evaluated, on the other hand, whether the addition of vitamin C can increase the incidence of gastrointestinal tract discomfort is aslo appraised , the discomfort include vomiting, nausea, abdominal pain, diarrhea and constipation. We hypothesis that vitamin C can increase the absorption of iron and accelerate the recovery of anemia, it also increases incidence of gastrointestinal adverse events because of increased iron absorption at the same time.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND Iron deficiency(ID) causes approximately half of all anemia cases worldwide, a moderate degree of iron-deficiency anemia(IDA) affected approximately 610 million people worldwide or 8.8% of the population. It is slightly more common in female (9.9%) than males (7.8%). In 2013, anemia due to iron deficiency resulted in about 183,000 deaths. IDA is an urgent problem to be solved.

Iron deficiency anemia(IDA) is anemia due to not enough iron. Anemia is defined as a decrease in the amount of red blood cells (RBCs) or hemoglobin in the blood. It is caused by insufficient dietary intake and absorption of iron, or iron loss from bleeding. In babies and adolescents, rapid growth may outpace dietary intake of iron, and result in deficiency without disease or grossly abnormal diet. In women of childbearing age, heavy or long menstrual periods can also cause mild iron-deficiency anemia. Anemia is sometimes treatable, but certain types of anemia may be lifelong. If the cause is dietary iron deficiency, eating more iron-rich foods, such as beans, lentils or red meat, or taking iron supplements will usually correct the anemia.

In clinic, IDA clinically divided into three stages: ID, iron deficiency erythropoiesis (iron deficiency erythropoiesis, IDE) and IDA. The first stage is the reduction of iron storage, and there is a history of inadequate iron absorption; the second stage is the IDE, in addition to iron reduction or lack of external storage, transferrin is also reduced, the intake of iron in red blood cells is reduced compared to normal condition at this time; IDA is the last stage of iron deficiency. If the patients are diagnosed with ID and this condition can be corrected by diet therapy; if it reaches the IDA criteria, it's need to take iron orally and improve symptoms as soon as possible, but the most important is to find the cause of iron deficiency. Ferrous succinate is commonly used to treat IDA in clinic, mainly absorbed in the duodenum and proximal jejunum in the form of ferrous iron. In health people, 5% to 10% of the iron are absorbed after taken orally. the absorption proportion is increased to 20%~30% in IDA patients. After absorbed, ferrous iron can bind to transferrin and enter the blood circulation, and then involve in the production of red blood cells as raw materials. In clinical practice, the doctor will prescribe ferrous succinate with or without vitamin C according to their own preferences. Vitamin C Involves in many biological processes in vivo, such as, collagen formation, tissue repair, the synthesis of phenylalanine, tyrosine, metabolism of folic acid, iron and maintains vascular integrity. Researchers have shown that increased iron intake with vitamin C can prevent anemia,the application of vitamin C can reduce the toxicity symptoms in genotoxic caused by ferric iron, it demonstrates that vitamin C is safe when combined with ferrous succinate. In theory, only the divalent iron can be absorbed in the duodenum and upper jejunum, vitamin C can oxidize ferric iron into divalent iron and maintains a certain degree of acidity in the intestine, and then promotes the absorption of iron. However, the feasibility in theory can not represent the clinical practice. So it's necessary to explore the efficacy and safety of vitamin C for iron supplementation in adult IDA patients through randomized controlled trial(RCT).

PROCEDURE Before the start of this study, the manila envelope is used to carry out the random allocation scheme, different treatment options are randomly loaded into the envelope according to the randomization generated by Stata 11.0 software. In terms of the inclusion criteria, We write the serial number of patients on the envelope after signing informed consent form and give different treatments according to the internal treatment option in envelope. In addition to the above treatment, increased intake of protein, calcium, iron, vitamins and essential fatty acids, appropriate heat are also advised at the same time. In order to check the compliance of the subject, the drug package and aluminum cardboard are asked to return to researchers at follow-up every two weeks, patients should be emphasized that they return all the drug packages, including the pharmaceutical packages that are not taken and run out of, which will help researchers to analyze the patient medication correctly. The number of tablets is to count and determine how much of the remaining drugs and the drugs the patients have taken. During the period of study, patients who participate in this study are not allowed to use other drugs that may affect the effect of iron supplementation. In special circumstances, the patient will be excluded because of using other drugs that affect the absorption of iron or vitamin C. The patients will receive blood routine examination at follow-up every two weeks, the results of examination,the reason and number of termination and loss, the incidence of adverse events in patients, such as, nausea, vomiting, abdominal pain, diarrhea and constipation are all recorded. Finally, we analyze the data to determine the effect and safety of vitamin C for iron supplementation. In this study, we hypothesis that vitamin C can increase the absorption of iron and accelerates the recovery of anemia, it also increases the incidence of gastrointestinal adverse events because of increased iron absorption at the same time.

Study Type

Interventional

Enrollment (Actual)

440

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shanghai
      • Shanghai, Shanghai, China, 200040
        • Hushan Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hemoglobin (Hb) < 120 g/L in men and Hb < 110 g/L in women; Mean Corpuscular Volume(MCV) < 80 fl, Mean Corpuscular Hemoglobin(MCH) < 27 pg, and Mean Corpuscular Hemoglobin Concentration(MCHC) < 0.32; the blood biochemical examination: serum ferritin < 12 g/L, serum iron < 8.95 mol/L, transferrin saturation <15%, and total iron binding capacity>64.44 mol/L; with a history of Menorrhagia, monophagia or eating disorders; Willing to sign a Informed consent form.

Exclusion Criteria:

  • Pregnant women; drug allergy; the patients with serious gastrorrhagia, other peptic ulcers, active bleeding, hepatic insufficiency, heart disease or renal insufficiency; those patients can't tolerate the medicine orally, or participate in other clinical study, or refuse to sign a Informed consent Form.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ferrous succinate and vitamin C
In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
Drug: ferrous succinate and vitamin C
As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
Active Comparator: ferrous succinate with normal dosage
In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
Drug: ferrous succinate
As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
Drug: ferrous succinate
As another active comparator, patients take the tablets of ferrous succinate with double dosage
Active Comparator: ferrous succinate with double dosage
In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
Drug: ferrous succinate
As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
Drug: ferrous succinate
As another active comparator, patients take the tablets of ferrous succinate with double dosage

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemoglobin
Time Frame: two weeks
The increased levels of hemoglobin after receiving three different treatment regimens are evaluated in the second week
two weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reticulocyte
Time Frame: two weeks
The increased levels of reticulocyte after receiving three different treatment regimens are evaluated in the second week
two weeks
Hemoglobin
Time Frame: four weeks
The increased levels of hemoglobin after receiving three different treatment regimens are evaluated in the fourth week
four weeks
Ferritin
Time Frame: eight weeks
The increased levels of ferritin after receiving three different treatment regimens are evaluated in the eighth week
eight weeks
adverse events
Time Frame: every two weeks
The incidence of adverse events every two weeks are assessed, the adverse events include bellyache, diarrhea, constipation, vomiting, nausea.
every two weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Huashan Hospital

Investigators

  • Principal Investigator: Qin X Wang, doctorate, Huashan Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

December 14, 2015

First Submitted That Met QC Criteria

December 15, 2015

First Posted (Estimate)

December 16, 2015

Study Record Updates

Last Update Posted (Actual)

February 25, 2019

Last Update Submitted That Met QC Criteria

February 21, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KY2015-270

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anemia, Iron-Deficiency

Clinical Trials on ferrous succinate and vitamin C

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe